Author: lifemolecular

Click here to read more: Press release

Click to read more: Research Presented Provides Further Insights into Amyloid and Tau Imaging Agents

Click to read more: Life Molecular Imaging teams up with ITELPHARMA for supply and production of NeuraCeq in Puglia, Italy

Click to read more: Investigational tau imaging agent PI-2620 added to the existing imaging biomarker platform for research studies in Chile. First patients have been examined.

Click to read more: Research presented provides insights into LMI compounds comprising Neuraceq (florbetaben 18F), PI-2620, RM2, GP1 and FSPG.

Click to read more: The new study will thoroughly assess the accumulation and spread of Tau depositions in patients with Alzheimer’s disease and in subjects with mild cognitive impairment as visualized by PI-2620 brain uptake

Read more: NeuraCeq (florbetaben) will be soon available in The Philippines

Read more: Brain imaging research study with amyloid and tau PET to investigate aging Thai individuals aiming for development of models for a healthier life in the Thai society

Read more: Improved supply capabilities of NeuraCeq in the Communities of Catalonia and Aragon through the collaboration with IRAB. Investigational tau imaging agent PI-2620 added to the imaging biomarker platform for research studies.

Read more: Publication of IDEAS study aim 1 results shows that Amyloid PET Imaging was associated with changes in clinical management for Medicare beneficiaries with MCI, dementia, cognitive impairment or Alzheimer’s Disease